Stock Ratings / Health Care / VCEL / financials

BCRX (78) MESO (60) VIR (31) ALVO (58) ⌘ Pro Terminal →

Vericel Corporation (VCEL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$42.91 +4.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Vericel Corporation (VCEL) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $2.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCEL)Realized 20D OHLCV Swing Band: ±8.3%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How VCEL Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$24.7M (9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $197.5M

FY24

Rev $237.2M

FY25

Rev $276.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$276.3M	74.4%	4%	$16.5M	$24.7M	3.4%
FY 2024	$237.2M	72.6%	1.9%	$10.4M	-$5.8M	1.6%
FY 2023	$197.5M	74.4%	-3.3%	-$3.2M	$35.3M	3.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VCEL)

✓Walkthrough of VCEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.55%⚡ TESTING RESISTANCE

2026-10-30O $43.02H $43.02L $40.01C $42.91VOL 598.7K

RES: $43.47SUP: $40.08SMA50: $40.58SMA200: $38.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCEL Butterfly Map → + Track VCEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCEL)

Health Care Rank #118 of 1016 ⚔️ BCRX vs VCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCEL vs. BCRX, MESO, VIR, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vericel Corporation (VCEL) ranks #118 by composite RQD confidence (67/100, grade C+) and #245 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with VCEL at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VCEL ACTIVE Vericel Corporation	C+	67/100	133.0x	74.4%	3.4%	+4.43%	$2.20B	Benchmark Subject
BCRX BioCryst Pharmaceuticals Inc.	B+	78/100	8.3x	—	85.0%	+1.79%	$2.18B	/bcrx-vs-vcel →
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-vcel →
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-vcel →
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-vcel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000887359

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vericel Corporation (VCEL) reported GAAP revenue of $276.3M (+16.5% vs. FY2024 revenue of $237.2M , and +39.9% cumulative change since FY2023) , GAAP net income of $16.5M, operating cash flow of $51.9M, and free cash flow of $24.7M (+525.9% YoY). On the balance sheet, VCEL closed FY2025 with $488.0M in total assets against $0 in total debt (Altman Z-Score: 9.94, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$276.3M	$16.5M	$51.9M	$24.7M	$488.0M	—
FY2024 (FY)	2024-12-31	$237.2M	$10.4M	$58.2M	-$5.8M	$432.7M	—
FY2023 (FY)	2023-12-31	$197.5M	-$3.2M	$35.3M	$35.3M	—	—

3. VCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vericel Corporation (NASDAQ: VCEL) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $42.91 (+4.43% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, VCEL ranks #118 in composite RQD confidence.

How does VCEL compare to BCRX and MESO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VCEL carries a Roarable C+ (67/100 RQD), trailing P/E of 133.0x, gross margin of 74.4%, and ROIC of 3.4%. By comparison, BCRX (BioCryst Pharmaceuticals Inc.) holds a B+ grade (78/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.18B) and MESO (Mesoblast Limited) posts a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $2.04B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCEL?

Per VCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000887359), Vericel Corporation generated $276.3M in revenue (+16.5% YoY), $16.5M in net income, and $24.7M in free cash flow against $488.0M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

VCEL last traded at $42.91 (+4.43% on volume of 544,850 shares), positioning the stock +5.74% above its 50-day simple moving average ($40.58) and +11.02% above its 200-day simple moving average ($38.65). Across its 52-week range of $28.95 to $49.32, VCEL sits at the 68.5% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($39.35 to $46.47).